Showing results (571-580 of 631) with videos related to
Sort By:
Pageof 64
Journal of the American College of Cardiology|September 1, 1989
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PAA E Arnold, R W Brower, D Collen, et al.The Journal of Biological Chemistry|October 25, 1988
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)P J Declerck, M De Mol, M C Alessi, et al.American Heart Journal|April 27, 2000
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS)P W Armstrong, J R Burton, D Palisaitis, et al.Circulation|March 1, 1991
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, R C Leinbach, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 9, 2001
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularizationV Lambert, C Munaut, A Noël, et al.Journal of Thrombosis and Haemostasis : JTH|January 16, 2008
Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumoniaR Renckens, J J T H Roelofs, M E Stegenga, et al.The Journal of Pathology|June 24, 2008
Genetic loss of Gas6 induces plaque stability in experimental atherosclerosisE Lutgens, M Tjwa, P Garcia de Frutos, et al.Circulation|April 1, 1989
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysisI K Jang, H K Gold, A A Ziskind, et al.Journal of the American College of Cardiology|September 1, 1990
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparationT Yasuda, H K Gold, H Yaoita, et al.Journal of the American College of Cardiology|December 1, 1990
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibodyT Yasuda, H K Gold, R C Leinbach, et al.Pageof 64